Eyeworld

EW PRODUCT SHOWCASE 200 March 2018 LENSAR received 510(k) clearance from the U.S. FDA for IntelliAxis-L, a new feature with the latest LENSAR Laser System upgrade, Streamline IV. IntelliAxis-L is a unique reference mark that leverages the integrated preoperative diagnostic capabilities, iris regis- tration, and intraoperative imaging to identify the location of the steep corneal axis at the capsular plane for toric IOL alignment. LENSAR www.lensar.com IntelliAxis-L RxSight announced that the U.S. Food and Drug Administration (FDA) approved the Light Adjustable Lens and the Light Delivery Device for patients with pre-existing astigmatism of ≥0.75 D undergoing cataract surgery. The Light Adjustable Lens is the first and only FDA approved intraocular lens that can be adjusted postoperatively to improve uncorrected visual acuity. RxSight www.rxsight.com Light Adjustable Lens and Light Delivery Device Bausch + Lomb introduced the enVista MX60E with StableFlex technology. The enVista MX60E features AccuSet haptics, which provides extensive interaction with the capsular bag to aid in securing the lens position through its offset design and broad contact angle. The lens is Bausch + Lomb's latest addition to its Advanced Optics (AO) family of IOLs. Bausch + Lomb www.bausch.com enVista MX60E IOL Johnson & Johnson Vision announced that the CATALYS System Mobile Patient Bed received FDA clearance for sale in the U.S. Designed to optimize workflow from cataract patient preparation through postoperative recov- ery, the bed integrates seamlessly with the CATALYS System through Bluetooth connectiv- ity. The Mobile Patient Bed has an ergonom- ically designed headrest to optimize patient head positioning and an intuitive remote control pendant. Johnson & Johnson Vision www.jnjvc.com CATALYS System Mobile Patient Bed The MASK-it Eye Patch is a single-use, dis- posable, hygienic, and easy-to-use alternative to the pirate patch for monocular diagnostic testing (visual field or vision testing). This translucent patch is self-adherent and has a variable vault to accommodate the natural lashes. It is faster, cheaper, and cleaner than the pirate patch. It is available in rolls of 500 and can be ordered from the website. MASK-it Eye Patch MASK-it-EyePatch.com MASK-it Eye Patch Spark Therapeutics announced that Luxturna (voretigene neparvovec-rzyl) was approved by the U.S. FDA to treat patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. It is a one-time gene therapy to be used only in patients with mutations on both copies of the RPE65 gene who have sufficient viable retinal cells as determined by the treating physician. Voretigene neparvovec-rzyl is the first gene therapy for a genetic disease approved by the FDA and the first pharmaco- logic treatment for an inherited retinal disease. Spark Therapeutics sparktx.com Luxturna To be included in a future EyeWorld Product Showcase, email a description of your product along with a high resolution image to stacy@eyeworld.org.

• Blank Page
• Blank Page (1)